| Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments (NCT05371483) | Mayo Clinic | 2022-05-18 |
| Mainz Register of Patients With Sleep Disorders (NCT05321355) | Johannes Gutenberg University Mainz | 2022-02-01 |
| An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy (NCT05055024) | NLS Pharmaceutics | 2021-10-26 |
| A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE) (NCT05113745) | Axsome Therapeutics, Inc. | 2021-10-20 |
| A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy (NCT05059223) | Axsome Therapeutics, Inc. | 2021-09-15 |
| Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy (NCT04923594) | NLS Pharmaceutics | 2021-09-13 |
| Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration (NCT05008341) | Axsome Therapeutics, Inc. | 2021-08-27 |
| WAKIX® (Pitolisant) Pregnancy Registry (NCT05536011) | Harmony Biosciences Management, Inc. | 2021-08-24 |
| The Value of Combined Detection of Orexin-A, HLA Gene, PSG and MSLT in the Evaluation of Patients With Narcolepsy (NCT04940806) | Qianfoshan Hospital | 2021-05-01 |
| A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy (NCT04803786) | Jazz Pharmaceuticals | 2021-04-09 |
| An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy (NCT04794491) | Jazz Pharmaceuticals | 2021-03-22 |
| Anesthetic Management of Patients With Chronic Sleep Disorders (NCT04827329) | University Hospital, Montpellier | 2021-03-01 |
| A Study to Collect Information of People With Narcolepsy in Spain (NCT04667338) | Takeda | 2021-02-18 |
| Child and Adolescent Registry for Participants With Narcolepsy (NCT04899947) | Jazz Pharmaceuticals | 2020-10-10 |
| Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR) (NCT04647903) | Vallon Pharmaceuticals, Inc. | 2020-10-05 |
| Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia (NCT03626727) | Brigham and Women's Hospital | 2020-09-01 |
| Awareness and Self-Compassion Enhancing Narcolepsy Treatment (NCT04306952) | Northwestern University | 2020-06-15 |
| An Open Label Study of FT218 in Subjects With Narcolepsy (NCT04451668) | Avadel | 2020-06-12 |
| TElemedicine for NARcolepsy (NCT04316286) | Azienda Usl di Bologna | 2020-04-01 |
| Study of the Academic and Professional Course of Narcoleptic Patients (NARCOSCOL-NARCOVITAE) (NCT03765892) | Hospices Civils de Lyon | 2020-02-27 |
| International Swiss Primary Hypersomnolence and Narcolepsy Cohort Study (NCT04330963) | Insel Gruppe AG, University Hospital Bern | 2020-01-06 |
| Advancing Understanding of Transportation Options (NCT04141891) | University of Colorado, Denver | 2019-12-12 |
| 'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy' (NCT04419792) | University of Dublin, Trinity College | 2019-10-15 |
| A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy (NCT04072380) | Suven Life Sciences Limited | 2019-09-21 |
| SUNOSI® (Solriamfetol) Pregnancy Registry (NCT06413420) | Axsome Therapeutics, Inc. | 2019-07-31 |
| Pilot Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Abuse Liability of an Abuse-Deterrent Immediate-Release Formulation (ADAIR) (NCT04232644) | Vallon Pharmaceuticals, Inc. | 2019-05-27 |
| Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT) (NCT03881852) | Axsome Therapeutics, Inc. | 2019-04-05 |
| Development and Validation of Pediatric Narcolepsy Patient Reported Outcomes Scale (NCT05373979) | Boston Children's Hospital | 2019-04-02 |
| Psychosocial Adjunctive Treatment for Hypersomnia (PATH) (NCT03904238) | Northwestern University | 2018-12-10 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy (NCT03748979) | Takeda | 2018-11-21 |
| Exploration of the Reward System by Functional MRI in Narco-cataplexy Patients With and Without REM Sleep Behavior Disorder (NCT03425214) | University Hospital, Clermont-Ferrand | 2018-01-19 |
| A Study to Evaluate the Safety and Efficacy of TS-091 in Patients with Narcolepsy (NCT03267303) | Taisho Pharmaceutical Co., Ltd. | 2017-10-31 |
| Evaluation of Academic and Professional Trajectories of Narcoleptic Patients (NCT03173378) | Hospices Civils de Lyon | 2017-10-03 |
| Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy (NCT02720744) | Avadel | 2016-11-17 |
| The Effect of Caffeine on the Narcoleptic Patients (NCT02832336) | King Saud University | 2016-10-01 |
| Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients (NCT02821715) | Theranexus | 2016-09-01 |
| Narcolepsy Protect Against Alzheimer's Disease? (NCT03378453) | University Hospital, Montpellier | 2016-04-07 |
| Sleep and Memory in Children (NCT02785328) | Hospices Civils de Lyon | 2016-02-01 |
| Investigation of Clinical Feature and Brain Function in Narcoleptic Patients (NCT03376568) | Tang-Du Hospital | 2016-01-28 |
| Cardiovascular Variability and Heart Rate Arousal Response in Idiopathic Hypersomnia (NCT02913651) | Centre Hospitalier Universitaire de Saint Etienne | 2016-01-01 |
| A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy (NCT02769780) | Jazz Pharmaceuticals | 2015-07-08 |
| "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy" (NCT02348593) | Jazz Pharmaceuticals | 2015-05-01 |
| This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation. (NCT05015673) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2014-06-05 |
| Metabolism Characteristics in the Children With Narcolepsy (NCT02799849) | Hospices Civils de Lyon | 2013-12-20 |
| Neurophysiologic Correlates of Hypersomnia (NCT01719315) | University of Wisconsin, Madison | 2012-11-01 |
| Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV) (NCT01789398) | Bioprojet | 2012-09-01 |
| A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy (NCT01681121) | Jazz Pharmaceuticals | 2012-09-01 |
| Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy (NCT01624480) | Teva Branded Pharmaceutical Products R&D, Inc. | 2012-07-01 |
| A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness (NCT01485770) | Jazz Pharmaceuticals | 2011-12-01 |
| Risk of Narcolepsy Associated With Administration of H1N1 Vaccine (NCT01394614) | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | 2011-06-01 |
| Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant) (NCT01399606) | Bioprojet | 2011-05-01 |
| Clarithromycin for the Treatment of Hypersomnia (NCT01146600) | Lynn Marie Trotti | 2010-07-01 |
| Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies (NCT00916253) | University Hospital, Bordeaux | 2010-03-01 |
| A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy (NCT01006122) | Pfizer | 2009-11-01 |
| Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy (NCT01067235) | Bioprojet | 2009-10-01 |
| The Nuvigil and Provigil Pregnancy Registry (NCT01792583) | Cephalon, Inc. | 2009-06-30 |
| Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy (NCT01067222) | Bioprojet | 2009-05-01 |
| Effect of Intranasal Administration of Orexine A on IL-6-System, Sleep-Wake-Regulation and Neurocognition (NCT00484757) | Zentrum für Integrative Psychiatrie | 2007-06-01 |
| A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy (NCT00424931) | Alza Corporation, DE, USA | 2007-01-01 |
| Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy (NCT00366080) | GlaxoSmithKline | 2006-11-01 |
| Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ® on Prescription (NCT00244465) | UCB Pharma | 2006-05-01 |
| Body Weight Regulation in Patients With Narcolepsy (NCT00283894) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2006-01-20 |
| Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome (NCT00228566) | Cephalon | 2005-10-01 |
| Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive Sleepiness (NCT00214968) | Cephalon | 2005-01-01 |
| PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome (NCT00107848) | Cephalon | 2004-10-01 |
| Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy (NCT00107796) | Cephalon | 2004-10-01 |
| Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness (NCT00228553) | Cephalon | 2004-05-01 |
| Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy (NCT00078377) | Cephalon | 2004-03-01 |
| Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (NCT00078312) | Cephalon | 2004-01-01 |
| Provigil (Modafinil) Study by Taiwan Biotech Co. (NCT00174174) | National Taiwan University Hospital | 2003-09-01 |
| Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy (NCT00066170) | Jazz Pharmaceuticals | 2003-04-01 |
| Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic Patients (NCT00049803) | Orphan Medical | 2000-12-01 |
| Sleep Disorders of Patients With Diseases of the Nervous System (NCT00001664) | National Institute of Neurological Disorders and Stroke (NINDS) | 1996-12-04 |
| Expanded Access to SUVN-G3031 (Samelisant) for the Treatment of Subjects With Narcolepsy (NCT05530447) | Suven Life Sciences Limited | |
| Narcolepsy - New Potential Treatment (NCT02077036) | Karolinska University Hospital | |